Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study (Q33405858)

26 July 2017

title

Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study (English)

1 reference

multicenter clinical trial

26 July 2017

main subject

0 references

1 reference

1 reference

10

D Damotte

0 references

Christos Chouaid

11

object named as

C Chouaid

1 reference

26 July 2017

J Le Treut

1

1 reference

26 July 2017

M C Sault

2

1 reference

26 July 2017

H Lena

3

1 reference

26 July 2017

P J Souquet

4

1 reference

26 July 2017

A Vergnenegre

5

1 reference

26 July 2017

H Le Caer

6

1 reference

26 July 2017

H Berard

7

1 reference

26 July 2017

S Boffa

8

1 reference

26 July 2017

I Monnet

9

1 reference

26 July 2017

publication date

13 February 2013

1 reference

26 July 2017

1 reference

26 July 2017

volume

24

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

1548-1552

1 reference

Advances in neuroendocrine lung tumors

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

Neuroendocrine neoplasms of the lung: a prognostic spectrum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

Large-cell neuroendocrine carcinoma of the lung: an aggressive neuroendocrine lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

Large cell/neuroendocrine carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

Pulmonary large cell neuroendocrine carcinoma: a true high-grade neuroendocrine tumor needing prospective therapeutic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT009

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT009

1 reference

26 July 2017

1 reference